Company intelligence / Profile preview

Xcovery

Palm Beach Gardens, Florida, United Statesxcovery.com ↗

Ownership: Private
Development stage: Commercial

Overview

Xcovery has developed next-generation small molecule tyrosine kinase inhibitors for oncology; its lead asset, ensartinib, an ALK inhibitor, is approved in China for first-line treatment of ALK-positive non-small cell lung cancer. Other programs target EGFR, PDGFR, VEGFR, and mTOR pathways, with varying stages of development, including some discontinued and some in early clinical stages. Xcovery is seeking partners to launch ensartinib in the US and globally, and to develop combination therapies.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

ensartinib

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

Betta Pharmaceuticals (via leadership and collaboration)Global partners for drug development and commercialization

Beyond the preview

Go deeper on Xcovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcovery.

Explore the full profile